Cannabinoid Phosphate Prodrugs for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cannabidiol (CBD) therapy is limited by its low oral bioavailability, extensive first-pass metabolism, and rapid redistribution into fatty tissues, leading to sub-therapeutic concentrations and the need for high doses to achieve effective systemic concentrations.
Innovation Solution
Development of cannabinoid prodrugs, such as those represented by Formula (I), which are designed to enhance physicochemical, pharmacological, and pharmacokinetic properties, including improved solubility and oral bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of CBD are administered to achieve effective systemic concentrations, then therapeutic efficacy is improved, but the risk of side effects and metabolic burden increases
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of CBD through phosphate esterification. This transformation changes the physicochemical properties of the compound, specifically improving water solubility and altering pharmacokinetic parameters such as absorption rate and bioavailability. The prodrug approach allows the compound to achieve effective plasma concentrations at lower doses, thereby reducing side effects and metabolic burden while maintaining therapeutic efficacy.
2Ease of operation
If oral CBD is administered, then ease of administration is improved, but bioavailability remains very low due to extensive first-pass metabolism
Solution Approach 1:
The patent employs an intermediary approach by introducing a phosphate group as a prodrug moiety. This phosphate group acts as a mediator that temporarily modifies the CBD molecule to enhance its solubility and absorption characteristics. The phosphate prodrug serves as an intermediate form that is more readily absorbed in the gastrointestinal tract and can bypass some of the limitations of first-pass metabolism, thereby improving oral bioavailability while maintaining ease of administration.
3Reliability
If CBD is administered, then therapeutic effects are achieved, but rapid redistribution into fatty tissues leads to sub-therapeutic plasma concentrations
Solution Approach 1:
The patent applies parameter changes by modifying the lipophilicity of CBD through phosphate esterification. The phosphate group increases water solubility and decreases fat solubility, thereby altering the distribution pattern of the compound. This parameter change prevents rapid redistribution into fatty tissues and maintains more stable plasma concentrations over time, ensuring sustained therapeutic effects without requiring frequent dosing.
Data Source
AI summary
Phosphate prodrugs of cannabinoids are disclosed herein as are pharmaceutical compositions comprising one or more of the same. Such compounds and compositions are useful for the treatment of diseases, disorders, and/or conditions, including neurological disorders and neuropathic pain.